ReviewInternational journal of molecular sciences2025
The Roles of tRNA-Derived Fragments in Cancer: Updates and Perspectives.
Review in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- tRF-3017b promotes prostate cancer progression by enhancing cell proliferation, CTL resistance, and M2 macrophage polarization.Scientific reports · 2026Article
- Non-coding RNA regulation of the radiation-induced DNA damage response and its translational relevance.Discover oncology · 2026Review
- Transfer RNA expression, modification, and derived small RNAs in cancer biology and clinical potential.Frontiers in immunology · 2026Review
- Transfer RNA-derived fragment tRF-28-P4R8YP9LOND5 as a novel serum biomarker for gastric cancer: diagnostic efficacy and clinicopathological correlations.Translational cancer research · 2025Article
- Peripheral blood tRNA-derived fragments as novel noninvasive biomarkers for diagnosis and prognostic stratification in multiple myeloma.Frontiers in immunology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Non-coding RNAs (ncRNAs) and the significant roles they play in several diseases have been described and verified in numerous studies. Transfer RNA (tRNA)-derived fragments (tRFs) are a newly discovered class of small ncRNAs produced by mature or precursor tRNAs. In light of the development of RNA sequencing, evidence has shown that tRFs are widely involved in the generation and progression of diseases through a series of mechanisms, including RNA silencing, translational regulation, epigenetic regulation, reverse-transcriptional regulation, and cellular apoptosis. Several studies have determined that tRFs participate in several cancers in a number of ways. Furthermore, novel tRFs may hold significant potential as both diagnostic biomarkers and therapeutic targets in clinical applications. In this review, we discuss the biogenesis and classification of tRFs, illustrate their fundamental functions, and summarize the most recent tRF-related discoveries pertaining to cancer.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.